Linked Life Data

17239271

Source:http://linkedlifedata.com/resource/pubmed/id/17239271

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-1-22
pubmed:abstractText
Prostate cancer is a complex heterogeneous disease, and risk stratification remains a significant clinical challenge. Gene microarray has been developed to provide better prediction of clinical outcomes and potentially improve management of patients with various malignancies, including prostate cancer. Currently, several studies are evaluating the clinical significance of gene expression signatures in prostate cancer. These approaches might provide outcome predictions, such as treatment response, progression-free survival, overall survival, and metastatic status and offer new strategies to identify patients at high risk for personalized cancer therapies. This article discusses the latest developments in gene expression-based signatures that predict clinical behavior of prostate cancer. Gene profiling could lead to enhanced early detection and prognosis of prostate cancer, resulting in improved overall survival. The ability to predict clinical outcomes by the microarray-derived genetic signatures is promising; however, further studies are warranted to optimize its clinical utility in patients with prostate cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1558-7673
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
187-9
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer.
pubmed:affiliation
CIG Media Group, LP, Dallas, TX, USA.
pubmed:publicationType
Journal Article, Review